Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LVTX
stocks logo

LVTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.259
+84.54%
--
--
-0.211
+62.35%
--
--
-0.202
-36.9%
Estimates Revision
The market is revising No Change the revenue expectations for LAVA Therapeutics N.V. (LVTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 10.83%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+10.83%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for LAVA Therapeutics NV (LVTX.O) is -2.08, compared to its 5-year average forward P/E of -2.01. For a more detailed relative valuation and DCF analysis to assess LAVA Therapeutics NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.01
Current PE
-2.08
Overvalued PE
-0.74
Undervalued PE
-3.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.29
Undervalued EV/EBITDA
-1.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
97.95
Current PS
0.00
Overvalued PS
302.26
Undervalued PS
-106.36
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

LVTX News & Events

Events Timeline

(ET)
2025-11-21
07:47:25
Xoma Completes Acquisition of Lava Therapeutics
select
2025-11-13 (ET)
2025-11-13
07:41:40
Lava Therapeutics plans to withdraw from Nasdaq listing
select
2025-10-17 (ET)
2025-10-17
11:46:40
Xoma and Lava Therapeutics Reveal Changes to Purchase Agreement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-21Globenewswire
XOMA Royalty Completes Acquisition of LAVA Therapeutics N.V.

  • Acquisition Announcement: XOMA Royalty Corporation has completed its acquisition of LAVA Therapeutics N.V., with LAVA shareholders receiving $1.04 in cash per share and a contingent value right (CVR) for potential future payments.

  • Strategic Benefits: The acquisition is expected to enhance XOMA's portfolio by adding two early-stage bispecific antibodies developed in collaboration with major oncology partners, potentially driving significant value for both XOMA and LAVA shareholders.

  • Tender Offer Details: The tender offer for LAVA shares concluded with approximately 91.1% of outstanding shares validly tendered, leading to a corporate reorganization that resulted in XOMA acquiring 100% of LAVA.

  • Future Outlook: XOMA Royalty emphasizes the potential for future economic benefits from LAVA's partnered and unpartnered programs, while also cautioning that forward-looking statements regarding these benefits are subject to various risks and uncertainties.

[object Object]
Preview
8.5
11-13Newsfilter
LAVA Reports Surpassing Minimum Requirement in Tender Offer and Plans to Withdraw from Nasdaq

  • Tender Offer Success: LAVA Therapeutics announced that approximately 87% of its outstanding common shares were validly tendered in the offer from XOMA Royalty, satisfying the minimum tender condition for the acquisition.

  • Subsequent Offering Period: A subsequent offering period has begun for LAVA shareholders who have not yet tendered their shares, which will end on November 20, 2025, with shares expected to be suspended from trading on Nasdaq shortly thereafter.

  • Voluntary Delisting: LAVA has notified Nasdaq of its intention to voluntarily delist its common shares, contingent upon the completion of the acquisition by XOMA Royalty.

  • Forward-Looking Statements: The press release includes cautionary notes regarding forward-looking statements, highlighting various risks and uncertainties that could affect the completion of the tender offer and LAVA's business operations.

[object Object]
Preview
7.0
10-20PRnewswire
Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement

  • Investigation Announcement: The Ademi Firm is investigating Lava (Nasdaq: LVTX) for potential breaches of fiduciary duty related to its transaction with XOMA Royalty, including concerns over the terms of the deal and the conduct of Lava's board of directors.

  • Transaction Details: Under the amended agreement, Lava shareholders will receive a reduced initial cash amount of $1.04 per share and a contingent value right, while the minimum net-cash closing condition has been lowered from $31.5 million to $24.5 million, raising concerns about the limitations on competing bids.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is LAVA Therapeutics NV (LVTX) stock price today?

The current price of LVTX is 1.77 USD — it has decreased -4.02 % in the last trading day.

arrow icon

What is LAVA Therapeutics NV (LVTX)'s business?

LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

arrow icon

What is the price predicton of LVTX Stock?

Wall Street analysts forecast LVTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LVTX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is LAVA Therapeutics NV (LVTX)'s revenue for the last quarter?

LAVA Therapeutics NV revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is LAVA Therapeutics NV (LVTX)'s earnings per share (EPS) for the last quarter?

LAVA Therapeutics NV. EPS for the last quarter amounts to -0.27 USD, decreased -41.30 % YoY.

arrow icon

What changes have occurred in the market's expectations for LAVA Therapeutics NV (LVTX)'s fundamentals?

The market is revising No Change the revenue expectations for LAVA Therapeutics N.V. (LVTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 10.83%.
arrow icon

How many employees does LAVA Therapeutics NV (LVTX). have?

LAVA Therapeutics NV (LVTX) has 34 emplpoyees as of December 05 2025.

arrow icon

What is LAVA Therapeutics NV (LVTX) market cap?

Today LVTX has the market capitalization of 49.43M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free